DDrare: Database of Drug Development for Rare Diseases

215. ファロー四徴症
［臨床試験数：19，薬物数：35（DrugBank：16），標的遺伝子数：16，標的パスウェイ数：47］

Searched query = "Tetralogy of Fallot", "Fallot tetralogy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AS; CPX; Calcium; Calcium gluconate; Coenzyme Q10; Device: Cellvizio 100 Series System with Confocal Miniprobes; Dexmedetomidine; Dobutamin; Dobutamine; Eplerenone; Fentanyl; Fentanyl (High Dose); Fentanyl (Low Dose); Fentanyl (Low Dose) + Dexmedetomidine; Fluorescite; Gradient; Ketamine; LOSARTAN POTASSIUM; Losartan; Losartan Potassium; Other: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.; Other: dobutamine; PV; Potassium; Procedure: B-lines SE; Procedure: Coronary flow reserve SE; Procedure: Diastolic function SE; Procedure: Left ventricular contractile reserve SE; Procedure: Left ventricular outflow tract gradient SE; Procedure: Mitral regurgitation SE; Procedure: Pulmonary hemodynamics SE; Procedure: TOF repair with trans-annular patch VS preservation of PV; Recombinant human brain natriuretic peptide (rhBNP); Sodium citrate; Tranexamic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04017975 (ClinicalTrials.gov)	December 20, 2019	10/7/2019	Optical Tissue Identification for Myocardial Architecture	Optical Tissue Identification for Myocardial Architecture (OPTIMA Study)	Ventricular Septal Defect;Complete Atrioventricular Canal;Tetralogy of Fallot With Pulmonary Stenosis	Drug: Fluorescite;Device: Cellvizio 100 Series System with Confocal Miniprobes	Aditya Kaza	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	N/A	18 Years	All	70	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04017975
(ClinicalTrials.gov)

December 20, 2019

10/7/2019

Optical Tissue Identification for Myocardial Architecture

Optical Tissue Identification for Myocardial Architecture (OPTIMA Study)

Ventricular Septal Defect;Complete Atrioventricular Canal;Tetralogy of Fallot With Pulmonary Stenosis

Drug: Fluorescite;Device: Cellvizio 100 Series System with Confocal Miniprobes

Aditya Kaza

National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

N/A

18 Years

All

Phase 2

United States